{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:01Z","timestamp":1792114081981,"version":"4.4.0"},"publisher-location":"Chichester, UK","reference-count":107,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006539.pub3","type":"reference-entry","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T01:16:59Z","timestamp":1361582219000},"source":"Crossref","is-referenced-by-count":18,"title":["Neuroprotection for treatment of glaucoma in adults"],"prefix":"10.1002","author":[{"given":"Dayse F","family":"Sena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB1|cit1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajo.2011.07.009","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-pressure Glaucoma Treatment Study","volume":"152","author":"Garudadri","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006539.pub3-BIB4|cit2","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/sj.eye.6702890","article-title":"A clinical trial studying neuroprotection in low-pressure glaucoma","volume":"21","author":"Krupin","year":"2007","journal-title":"Eye"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB5|cit3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3129\/i07-043","article-title":"Special considerations in low-tension glaucoma","volume":"42","author":"Krupin","year":"2007","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB2|cit4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study","volume":"151","author":"Krupin","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB3|cit5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ophtha.2004.10.034","article-title":"The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients","volume":"112","author":"Krupin","year":"2005","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB6|cit6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.ajo.2011.06.019","article-title":"The rate of progression and ocular perfusion pressure in the Low-pressure Glaucoma Treatment Study","volume":"152","author":"Quaranta","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006539.pub3-BIB7|cit7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archopht.122.7.957","article-title":"A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma","volume":"122","author":"Alm","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB8|cit8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0002-9394(03)00478-1","article-title":"Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma","volume":"136","author":"Anderson","year":"2003","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB9|cit9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10384-010-0815-z","article-title":"Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study","volume":"54","author":"Araie","year":"2010","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB10|cit10","first-page":"213","article-title":"Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma","volume":"115","author":"Araie","year":"2011","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"1","key":"10.1002\/14651858.CD006539.pub3-BIB11|cit11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.preteyeres.2010.09.002","article-title":"Use of calcium channel blockers for glaucoma","volume":"30","author":"Araie","year":"2011","journal-title":"Progress in Retinal and Eye Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006539.pub3-BIB12|cit12","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1016\/S0039-6257(01)00202-8","article-title":"Assessment of the retinal nerve fiber layer in clinical trials of glaucoma neuroprotection","volume":"45","author":"Blumenthal","year":"2001","journal-title":"Survey of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB13|cit13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1517\/13543784.6.8.1063","article-title":"Brimonidine","volume":"6","author":"Cantor","year":"1997","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"229","key":"10.1002\/14651858.CD006539.pub3-BIB14|cit14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1600-0420.1999.tb01152.x","article-title":"The use of polyunsaturated fatty acids in ocular hypertension. A study with blue-on-yellow perimetry","volume":"77","author":"Cellini","year":"1999","journal-title":"Acta Ophthalmologica Scandinavica Supplement"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB15|cit15","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1167\/iovs.12-9483n","article-title":"Advances in glaucoma treatment and management: neurotrophic agents","volume":"53","author":"Chader","year":"2012","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB16|cit16","first-page":"307","article-title":"A clinical study of the neuroprotection effect of Erigeron Breviscapus Hand-Mazz on glaucomatous patient eyes","volume":"21","author":"Changhua","year":"2003","journal-title":"Chinese Ophthalmic Research"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB17|cit17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1607-551X(09)70310-9","article-title":"Rescula as an alternative therapy for beta-blockers with long-term drift effect in glaucoma patients","volume":"22","author":"Chen","year":"2006","journal-title":"Kaohsiung Journal of Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB18|cit18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10384-010-0855-4","article-title":"Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma","volume":"54","author":"Cho","year":"2010","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB19|cit19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0161-6420(00)00518-2","article-title":"Natural history of normal-tension glaucoma","volume":"108","author":"Anderson","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB20|cit20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures","volume":"126","year":"1998","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB21|cit21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","year":"1998","journal-title":"American Journal of Ophthalmology"},{"issue":"5-6","key":"10.1002\/14651858.CD006539.pub3-BIB22|cit22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10792-005-7581-9","article-title":"Evolving paradigms in the medical treatment of glaucoma","volume":"25","author":"Cohen","year":"2005","journal-title":"International Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB23|cit23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ajo.2011.06.015","article-title":"Clinical evidence for neuroprotection in glaucoma","volume":"152","author":"Cordeiro","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB24|cit24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/ICU.0b013e32834372ec","article-title":"Neuroprotection in glaucoma: recent and future directions","volume":"22","author":"Danesh-Meyer","year":"2011","journal-title":"Current Opinion in Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB25|cit25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00061198-199808000-00006","article-title":"A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma","volume":"7","author":"Drance","year":"1998","journal-title":"Journal of Glaucoma"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB26|cit26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00347-004-1152-8","article-title":"Early Manifest Glaucoma Trial update 2004","volume":"102","author":"Erb","year":"2005","journal-title":"Der Ophthalmologe"},{"issue":"10","key":"10.1002\/14651858.CD006539.pub3-BIB27|cit27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006539.pub3-BIB28|cit28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment","volume":"121","author":"Leske","year":"2003","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD006539.pub3-BIB29|cit29","unstructured":"Bartlett JD Evans DW Contrast sensitivity improvements in brimonidine-treated primary open-angle glaucoma patients suggest a neuroprotective mechanism Investigative Ophthalmology and Visual Science 2002 ARVO E-abstract 2201"},{"issue":"12","key":"10.1002\/14651858.CD006539.pub3-BIB30|cit30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/bjo.87.12.1463","article-title":"Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection","volume":"87","author":"Evans","year":"2003","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB31|cit31","first-page":"18","article-title":"The effect of parenteral citicoline on visual functions and life quality of patients with primary open-angle glaucoma","volume":"127","author":"Frolov","year":"2011","journal-title":"Vestnik Oftalmologii"},{"key":"10.1002\/14651858.CD006539.pub3-BIB32|cit32","unstructured":"Gandolfi SA Sangermani C Cimino L Ungaro N Tardini M Viswanathan A Is there a non IOP-related effect of brimonidine on visual field progression in human glaucoma? Investigative Ophthalmology and Visual Science 2004 ARVO E-abstract 2298"},{"key":"10.1002\/14651858.CD006539.pub3-BIB33|cit33","unstructured":"Garcia-Medina JJ Garcia-Medina M Garrido-Fernandez P Galvan-Espinosa J A 2-year follow-up of antioxidant supplementation in primary open-angle glaucoma Ophthalmic Research. Conference: SIRCOVA-ARVO Congress 2011. Valencia, Spain 2011"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB34|cit34","first-page":"385","article-title":"Glaucoma neuroprotection--how far is it from a dream to reality","volume":"44","author":"Ge","year":"2008","journal-title":"Chung-Hua Yen Ko Tsa Chih - Chinese Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB35|cit35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0002-9394(14)72604-2","article-title":"Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma","volume":"120","author":"Harris","year":"1995","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB36|cit36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1089\/jop.1999.15.189","article-title":"Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma","volume":"15","author":"Harris","year":"1999","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006539.pub3-BIB37|cit37","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/S0039-6257(02)00322-3","article-title":"Medical treatment of normal tension glaucoma","volume":"47","author":"Hoyng","year":"2002","journal-title":"Survey of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB38|cit38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/jop.2004.20.393","article-title":"Short-term effects of Bimatoprost in glaucoma patients from an outpatient clinic","volume":"20","author":"Iester","year":"2004","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB39|cit39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1034\/j.1600-0420.2003.00049.x","article-title":"The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial","volume":"81","author":"Inan","year":"2003","journal-title":"Acta Ophthalmologica Scandinavica"},{"key":"10.1002\/14651858.CD006539.pub3-BIB40|cit40","first-page":"598","article-title":"Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial","volume":"87","author":"Kass","year":"1989","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB41|cit41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-0420.1995.tb00274.x","article-title":"The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma","volume":"73","author":"Kjellgren","year":"1995","journal-title":"Acta Ophthalmologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB42|cit42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00061198-199904000-00006","article-title":"Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure","volume":"8","author":"Koseki","year":"1999","journal-title":"Journal of Glaucoma"},{"issue":"12","key":"10.1002\/14651858.CD006539.pub3-BIB43|cit43","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/S0161-6420(02)01247-2","article-title":"Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients","volume":"109","author":"Liu","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006539.pub3-BIB44|cit44","first-page":"41","article-title":"The effect of 1% apraclonidine on visual field parameters in patients with glaucoma and ocular hypertension","volume":"30","author":"Mastropasqua","year":"1998","journal-title":"Annals of Ophthalmology-Glaucoma"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB45|cit45","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0161-6420(03)00476-7","article-title":"Evaluation of neuroprotective qualities of brimonidine during LASIK","volume":"110","author":"McCarty","year":"2003","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB46|cit46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/bjo.84.6.579","article-title":"A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group","volume":"84","author":"O'Donoghue","year":"2000","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB47|cit47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3341\/kjo.2011.25.5.323","article-title":"Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma","volume":"25","author":"Park","year":"2011","journal-title":"Korean Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD006539.pub3-BIB48|cit48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","article-title":"A comparison of the fixed combination of latanoprost and timolol with its individual components","volume":"240","author":"Pfeiffer","year":"2002","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB49|cit49","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0161-6420(93)31603-9","article-title":"Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy","volume":"100","author":"Robin","year":"1993","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB50|cit50","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0161-6420(96)30510-1","article-title":"Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma","volume":"103","author":"Rulo","year":"1996","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB51|cit51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0161-6420(96)30703-3","article-title":"Prevention of visual field defect progression with Brovincamine in eyes with normal-tension glaucoma","volume":"103","author":"Sawada","year":"1996","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD006539.pub3-BIB52|cit52","first-page":"1087","article-title":"Neuro-protective effects of yiyanming solution on visual function of glaucoma patient","volume":"28","author":"Wang","year":"2010","journal-title":"Chinese Ophthalmic Research"},{"key":"10.1002\/14651858.CD006539.pub3-BIB53|cit53","unstructured":"NCT00141882 Memantine in patients With chronic glaucoma clinicaltrials.gov\/ct2\/show\/NCT00141882"},{"key":"10.1002\/14651858.CD006539.pub3-BIB54|cit54","unstructured":"NCT00168350 Memantine in patients with chronic glaucoma clinicaltrials.gov\/ct2\/show\/NCT00168350"},{"key":"10.1002\/14651858.CD006539.pub3-BIB55|cit55","unstructured":"American Academy of Ophthalmology Primary open-angle glaucoma, preferred practice pattern San Francisco: American Academy of Ophthalmology,"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB56|cit56","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0161-6420(94)31171-7","article-title":"Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability","volume":"101","year":"1994","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD006539.pub3-BIB57|cit57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/archopht.1980.01020041015002","article-title":"Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects","volume":"98","author":"Armaly","year":"1980","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB58|cit58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00061198-199806000-00004","article-title":"Changing definition of glaucoma","volume":"7","author":"Bathija","year":"1998","journal-title":"Journal of Glaucoma"},{"issue":"Suppl 236","key":"10.1002\/14651858.CD006539.pub3-BIB59|cit59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0420.80.s236.2.x","article-title":"Epidemiology of angle-closure glaucoma","volume":"80","author":"Bonomi","year":"2002","journal-title":"Acta Ophthalmologica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB60|cit60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0002-9394(14)75421-2","article-title":"Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture","volume":"121","author":"Brubaker","year":"1996","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB61|cit61","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/OPX.0b013e31817841e5","article-title":"Neuroprotection in glaucoma: drug-based approaches","volume":"85","author":"Cheung","year":"2008","journal-title":"Optometry and Vision Science"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB62|cit62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00006324-198308000-00009","article-title":"Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma?","volume":"60","author":"Cockburn","year":"1983","journal-title":"American Journal of Optometry and Physiological Optics"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB63|cit63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1167\/iovs.07-1132","article-title":"Report from the NEI\/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium","volume":"49","author":"Csaky","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB64|cit64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajo.2009.03.029","article-title":"Neuroprotection: extrapolating from neurologic diseases to the eye","volume":"148","author":"Danesh-Meyer","year":"2009","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD006539.pub3-BIB65|cit65","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD006539.pub3-BIB66|cit66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/IJG.0b013e3181c4b0fe","article-title":"Lack of association of polymorphisms in elastin with pseudoexfoliation syndrome and glaucoma","volume":"19","author":"Fan","year":"2010","journal-title":"Journal of Glaucoma"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB67|cit67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ophtha.2007.04.055","article-title":"Retinal blood flow response to posture change in glaucoma patients compared with healthy subjects","volume":"115","author":"Feke","year":"2008","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006539.pub3-BIB68|cit68","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0161-6420(00)00343-2","article-title":"Accuracy of clinical estimates of intraocular pressure in Chinese eyes","volume":"107","author":"Foster","year":"2000","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB69|cit69","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/archopht.122.4.532","article-title":"Prevalence of open-angle glaucoma among adults in the Unites States","volume":"122","author":"Friedman","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006539.pub3-BIB70|cit70","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/bjo.82.10.1118","article-title":"Vertical cup\/disc ratio in relation to optic disc size: its value in the assessment of the glaucoma suspect","volume":"82","author":"Garway-Heath","year":"1998","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB71|cit71","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB72|cit72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00055735-199704000-00007","article-title":"New definitions of glaucoma","volume":"8","author":"Gupta","year":"1997","journal-title":"Current Opinion in Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB73|cit73","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1167\/iovs.08-2103","article-title":"Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine","volume":"50","author":"Hare","year":"2009","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB74|cit74","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1167\/iovs.05-1476","article-title":"Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma","volume":"47","author":"Hauser","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD006539.pub3-BIB75|cit75","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/01.ijg.0000212255.17950.42","article-title":"Distribution of optineurin sequence variations in an ethnically diverse population of low-tension glaucoma patients from the United States","volume":"15","author":"Hauser","year":"2006","journal-title":"Journal of Glaucoma"},{"issue":"10","key":"10.1002\/14651858.CD006539.pub3-BIB76|cit76","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD006539.pub3-BIB77|cit77","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB78|cit78","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrg1578","article-title":"Gene-environment interactions in human diseases","volume":"6","author":"Hunter","year":"2005","journal-title":"Nature Reviews Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB79|cit79","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1167\/iovs.08-2499","article-title":"Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina","volume":"50","author":"Ju","year":"2009","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD006539.pub3-BIB80|cit80","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/bjo.82.7.835","article-title":"Normal tension glaucoma - a practical approach","volume":"82","author":"Kamal","year":"1998","journal-title":"British Journal of Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006539.pub3-BIB81|cit81","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/S0039-6257(99)00027-2","article-title":"Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy","volume":"43","author":"Levin","year":"1999","journal-title":"Survey of Ophthalmology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006539.pub3-BIB82|cit82","first-page":"S11","article-title":"History of neuroprotection and rationale as a therapy for glaucoma","volume":"14","author":"Levin","year":"2008","journal-title":"American Journal of Managed Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006539.pub3-BIB83|cit83","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0039-6257(03)00008-0","article-title":"Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage","volume":"48","author":"Lipton","year":"2003","journal-title":"Survey of Ophthalmology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006539.pub3-BIB84|cit84","first-page":"S20","article-title":"Current management of glaucoma and the need for complete therapy","volume":"14","author":"McKinnon","year":"2008","journal-title":"American Journal of Managed Care"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB85|cit85","first-page":"70","article-title":"Neuroprotection with carotenoids in glaucoma","volume":"59","author":"Neacsu","year":"2003","journal-title":"Oftalmologia"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB86|cit86","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archopht.1997.01100150499009","article-title":"Nitric oxide synthase in the human glaucomatous optic nerve head","volume":"115","author":"Neufeld","year":"1997","journal-title":"Archives of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB87|cit87","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/00061198-199812000-00014","article-title":"New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration","volume":"7","author":"Neufeld","year":"1998","journal-title":"Journal of Glaucoma"},{"key":"10.1002\/14651858.CD006539.pub3-BIB88|cit88","unstructured":"National Collaborating Centre for Acute Care Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension National Institute for Health and Clinical Excellence guideline"},{"issue":"9","key":"10.1002\/14651858.CD006539.pub3-BIB89|cit89","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","article-title":"Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study","volume":"111","author":"Nouri-Mahdavi","year":"2004","journal-title":"Ophthalmology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006539.pub3-BIB90|cit90","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1177\/112067210301303S04","article-title":"Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy","volume":"13","author":"Osborne","year":"2003","journal-title":"European Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB91|cit91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1755-3768.2008.01459.x","article-title":"Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned","volume":"87","author":"Osborne","year":"2009","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD006539.pub3-BIB92|cit92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1350-9462(98)00014-7","article-title":"Neuronal death in glaucoma","volume":"18","author":"Quigley","year":"1999","journal-title":"Progress in Retinal and Eye Research"},{"issue":"12","key":"10.1002\/14651858.CD006539.pub3-BIB93|cit93","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/archopht.119.12.1819","article-title":"The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER","volume":"119","author":"Quigley","year":"2001","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB94|cit94","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"Number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB95|cit95","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/ICU.0b013e32834ff490","article-title":"Clinical trials for glaucoma neuroprotection are not impossible","volume":"23","author":"Quigley","year":"2012","journal-title":"Current Opinion in Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006539.pub3-BIB96|cit96","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0161-6420(03)00564-5","article-title":"Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey","volume":"110","author":"Ramakrishnan","year":"2003","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD006539.pub3-BIB97|cit97","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD006539.pub3-BIB98|cit98","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"6","key":"10.1002\/14651858.CD006539.pub3-BIB99|cit99","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00061198-199612000-00012","article-title":"Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration","volume":"5","author":"Schwartz","year":"1996","journal-title":"Journal of Glaucoma"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB100|cit100","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00055735-200004000-00007","article-title":"Neuroprotection: a new treatment modality for glaucoma?","volume":"11","author":"Schwartz","year":"2000","journal-title":"Current Opinion in Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006539.pub3-BIB101|cit101","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/jop.2008.0056","article-title":"Potential benefit of intraocular pressure reduction in normal-tension glaucoma in South Korea","volume":"25","author":"Seong","year":"2009","journal-title":"Journal of Ocular Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD006539.pub3-BIB102|cit102","article-title":"Classification of the glaucomas","volume-title":"The glaucomas","author":"Shields","year":"1996"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB103|cit103","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.1991.03470030069026","article-title":"Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey","volume":"266","author":"Tielsch","year":"1991","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1002\/14651858.CD006539.pub3-BIB104|cit104","article-title":"Medical interventions for primary open angle glaucoma and ocular hypertension","author":"C\u00a0Vass","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006539.pub3-BIB105|cit105","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1001\/archopht.117.11.1540","article-title":"Is neuroprotection a viable therapy for glaucoma?","volume":"117","author":"Weinreb","year":"1998","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006539.pub3-BIB106|cit106","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1167\/iovs.06-0757","article-title":"Erythropoietin promotes survival of retinal ganglion cells in DBA\/2J glaucoma mice","volume":"48","author":"Zhong","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD006539.pub3-BIB107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006539.pub2","article-title":"Neuroprotection for treatment of glaucoma in adults","author":"Sena","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006539.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006539.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:00:49Z","timestamp":1628532049000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006539.pub3"}},"subtitle":[],"editor":[{"given":"Dayse F","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":107,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006539.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717983006.793500543","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2013,2,28]]}}}